Literature DB >> 21773856

Androgen receptor W741C and T877A mutations in AIDL cells, an androgen-independent subline of prostate cancer LNCaP cells.

Takashi Otsuka1, Kazuhiro Iguchi, Kazuhiro Fukami, Kenichiro Ishii, Shigeyuki Usui, Yoshiki Sugimura, Kazuyuki Hirano.   

Abstract

The androgen-independent LNCaP (AIDL) cell line was generated by maintaining prostate cancer LNCaP cells in a hormone-deprived medium. Notably, synthetic androgen R1881-related gene response is attenuated in AIDL cells as compared to the parental LNCaP cells. The aim of this study was to clarify the mechanisms underlying androgen sensitivity in AIDL cells. We first examined the expression of androgen receptor (AR) and its co-regulators. However, no significant difference in mRNA expression was found between LNCaP and AIDL cells. Remarkably, AR protein levels were induced by R1881 and DHT in LNCaP cells, but not in AIDL cells. We next performed the cDNA sequencing to detect mutations in the AR gene. The T877A mutation was detected both in LNCaP and AIDL cells. Furthermore, AIDL cells harbored a missense substitution (TGG → TGT) in the AR gene, which caused a point mutation at codon 741 (W741C). Double T877A and W741C AR mutants have been previously reported to exhibit reduced androgen sensitivity. Hence, the low-androgen-sensitive responses of AIDL cells may be explained, at least in part, by AR gene mutations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21773856     DOI: 10.1007/s13277-011-0209-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

Review 2.  Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications.

Authors:  Mujib Rahman; Hiroshi Miyamoto; Chawnshang Chang
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

3.  Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.

Authors:  Masayasu Urushibara; Junichiro Ishioka; Nobuhiko Hyochi; Kazunori Kihara; Shuntaro Hara; Pratap Singh; John T Isaacs; Yukio Kageyama
Journal:  Prostate       Date:  2007-06-01       Impact factor: 4.104

Review 4.  New strategies for the medical treatment of prostate cancer.

Authors:  John T Isaacs
Journal:  BJU Int       Date:  2005-12       Impact factor: 5.588

5.  Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways.

Authors:  M D Sadar
Journal:  J Biol Chem       Date:  1999-03-19       Impact factor: 5.157

6.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.

Authors:  C W Gregory; B He; R T Johnson; O H Ford; J L Mohler; F S French; E M Wilson
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

Review 7.  Androgen receptor involvement in the progression of prostate cancer.

Authors:  H Suzuki; T Ueda; T Ichikawa; H Ito
Journal:  Endocr Relat Cancer       Date:  2003-06       Impact factor: 5.678

8.  Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo.

Authors:  Kenichiro Ishii; Tetsuya Imamura; Kazuhiro Iguchi; Shigeki Arase; Yuko Yoshio; Kiminobu Arima; Kazuyuki Hirano; Yoshiki Sugimura
Journal:  Endocr Relat Cancer       Date:  2009-03-17       Impact factor: 5.678

9.  Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.

Authors:  Nobuyuki Ishikura; Hiromitsu Kawata; Ayako Nishimoto; Ryo Nakamura; Nobuya Ishii; Yuko Aoki
Journal:  Prostate       Date:  2010-04-01       Impact factor: 4.104

Review 10.  Degradation and beyond: control of androgen receptor activity by the proteasome system.

Authors:  Tomasz Jaworski
Journal:  Cell Mol Biol Lett       Date:  2006       Impact factor: 5.787

View more
  7 in total

1.  Expression changes and regulation of AR and IGF-1 in PC3 prostate cancer cells treated with sexual hormones and flutamide.

Authors:  Da Yue Tong; Xin yao Wu; Hong yu Sun; Yi Jin; Zhuo wei Liu; Fang jian Zhou
Journal:  Tumour Biol       Date:  2012-08-31

2.  Identification of Triptophenolide from Tripterygium wilfordii as a Pan-antagonist of Androgen Receptor.

Authors:  Yang He; Meng Wu; Yangguang Liu; Quanjie Li; Xiaoyu Li; Laixing Hu; Shan Cen; Jinming Zhou
Journal:  ACS Med Chem Lett       Date:  2016-09-28       Impact factor: 4.345

3.  Quantitative synthesis of the association between the cytochrome P450 1A1 Ile462Val polymorphism and prostate cancer risk.

Authors:  Guangye Han; Yanjuan Ma; Pei Liu; Xiaoxia Wei; Xinjun Zhang; Feng Zhu
Journal:  Tumour Biol       Date:  2013-02-06

4.  Effects of 14 frequently used drugs on prostate-specific antigen expression in prostate cancer LNCaP cells.

Authors:  Kazuhiro Iguchi; Maki Hashimoto; Masafumi Kubota; Shuji Yamashita; Mitsuhiro Nakamura; Shigeyuki Usui; Tadashi Sugiyama; Kazuyuki Hirano
Journal:  Oncol Lett       Date:  2014-03-05       Impact factor: 2.967

5.  Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration.

Authors:  Kenichiro Ishii; Izumi Matsuoka; Takeshi Sasaki; Kohei Nishikawa; Hideki Kanda; Hiroshi Imai; Yoshifumi Hirokawa; Kazuhiro Iguchi; Kiminobu Arima; Yoshiki Sugimura
Journal:  J Clin Med       Date:  2019-09-03       Impact factor: 4.241

6.  Inhibition of androgen receptor expression with small interfering RNA enhances cancer cell apoptosis by suppressing survival factors in androgen insensitive, late stage LNCaP cells.

Authors:  Sang Soo Kim; Hee Joo Cho; Jung Yoon Kang; Hee Kyu Kang; Tag Keun Yoo
Journal:  ScientificWorldJournal       Date:  2013-02-06

7.  Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.

Authors:  Keisuke Takeda; Noboru Hara; Tsutomu Nishiyama; Masayuki Tasaki; Fumio Ishizaki; Yoshihiko Tomita
Journal:  BMC Cancer       Date:  2016-05-25       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.